SEC Form 4 · accession 0001179110-15-016163
AbbVie Inc. · ABBV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Henry O Gosebruch
Officer — Chief Strategy Officer
Period of report
Dec 9, 2015
Accepted (ET)
Dec 11, 2015 · 5:22 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001551152
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock, $0.01 par valueF1 | Dec 9, 2015 | A | 26,510 | $0.00 | A | 26,510 | D | |
| Common stock, $0.01 par valueF2 | Dec 9, 2015 | A | 64,540 | $0.00 | A | 91,050 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Performance vested restricted stock granted under the AbbVie 2013 Incentive Stock Program. The award has a 5-year term, with no more than 1/3 of the award vesting in any one year upon AbbVie reaching a minimum return on equity target. The award includes the right to have stock withheld for tax purposes.
- F2A retention award of restricted stock granted under the AbbVie 2013 Incentive Stock Program. The award vests in annual increments of 21,514 on 12/09/2016, 21,513 on 12/09/2017, and 21,513 on 12/09/2018. The award includes the right to have stock withheld for tax purposes.